Gene expression signature for spontaneous cancer regression in melanoma pigs

Neoplasia

Volumn 10, Issue 7, 2008, Pages 714-726

  Rambow, Florian ^a,b   Piton, Guillaume ^a,b   Bouet, Stephan ^a,b   Leplat, Jean Jaques ^a,b   Baulande, Sylvain ^c   Marrau, Angelique ^c   Stam, Mark ^a,b   Horak, Vratislav ^d   Vincent Naulleau, Silvia ^a,b  

^a CEMAGREF   (France)

^b DIF   (France)

^c Parc Scientifique de Luminy   (France)

^d INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER REGRESSION; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HAIR FOLLICLE; IMMUNE RESPONSE GENE; MELANOCYTE; MELANOMA; METASTASIS; MICROARRAY ANALYSIS; MINIPIG; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 45849107158     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08344     Document Type: Article

References (53)

1. Soengas MS and Lowe SW (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151.
2. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, and Chanmugam A (2006). Cutaneous malignant melanoma. Mayo Clin Proc 81, 500-507.
3. Everson TC and Cole WH (1966). Spontaneous Regression of Cancer. Philadelphia, PA: WB Saunders.
4. High WA, Stewart D, Wilbers CR, Cockerell CJ, Hoang MP, and Fitzpatrick JE (2005). Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol 53, 89-100.
5. Barnetson RS and Halliday GM (1997). Regression in skin tumours: a common phenomenon. Australas J Dermatol 38 (Suppl 1), S63-S65.
6. Abramova L, Slingluff CL Jr, and Patterson JW (2002). Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasize. J Cutan Pathol 29, 407-414.
7. Paredes BE (2007). Regression in malignant melanoma: definition, etiopathogenesis, morphology and differential diagnosis. Pathologe 28, 453-463.
8. Papac RJ (1998). Spontaneous regression of cancer: possible mechanisms. In Vivo 12, 571-578.
9. Vincent-Naulleau S, Lechalony C, Leplat JJ, Bouet S, Bailly C, Spatz A, Vielh P, Avril MF, Tricaud Y, Gruand J, et al. (2004). Clinical and histopathological characterization of cutaneous melanomas in the melanoblastoma-bearing Libechov minipig model. Pigment Cell Res 17, 24-35.
10. Du ZQ, Vincent-Naulleau S, Gilbert H, Vignoles F, Crechet F, Shimogiri T, Yasue H, Leplat JJ, Bouet S, Gruand J, et al. (2007). Detection of novel quantitative trait loci for cutaneous melanoma by genome-wide scan in the MeLiM swine model. Int J Cancer 120, 303-320.
11. Nam MJ, Kee MK, Kuick R, and Hanash SM (2005). Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma. J Biol Chem 280, 8260-8265.
12. Tsai S, Cassady JP, Freking BA, Nonneman DJ, Rohrer GA, and Piedrahita JA (2006). Annotation of the Affymetrix porcine genome microarray. Anim Genet 37, 423-424.
13. Rambow F, Malek O, Geffrotin C, Leplat JJ, Bouet S, Piton G, Hugot K, Bevilacqua C, Horak V, and Vincent-Naulleau S (2008). Identification of differentially expressed genes in spontaneously regressing melanoma using the MeLiM swine model. Pigment Cell Res 21, 147-161.
14. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19, 290-302.
15. Ryu B, Kim DS, Deluca AM, and Alani RM (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2, e594.
16. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98, 472-482.
17. Ryu B, Kim DS, Deluca AM, and Alani RM (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2, e594.
18. Kim JY, Tillison K, Zhou S, Wu Y, and Smas CM (2007). The major facilitator superfamily member Slc37a2 is a novel macrophage-specific gene selectively expressed in obese white adipose tissue. Am J Physiol Endocrinol Metab 293, E110-E120.
19. Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I, et al. (2006). VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 116, 2817-2826.
20. Shen Z, Crotti TN, Flannery MR, Matsuzaki K, Goldring SR, and McHugh KP (2007). A novel promoter regulates calcitonin receptor gene expression in human osteoclasts. Biochim Biophys Acta 1769, 659-667.
21. Kim K, Lee SH, Kim JH, Choi Y, and Kim N (2008). NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22, 176-185.
22. Erickson-Miller CL, Freeman SD, Hopson CB, D'Alessio KJ, Fischer EI, Kikly KK, Abrahamson JA, Holmes SD, and King AG (2003). Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes. Exp Hematol 31, 382-388.
23. Bakker AB, Baker E, Sutherland GR, Phillips JH, and Lanier LL (1999). Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 96, 9792-9796.
24. Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van EP, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A, et al. (2006). Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 103, 1428-1433.
25. + T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 13, 1053-1060.
26. Jackson JR, Patrick DR, Dar MM, and Huang PS (2007). Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7, 107-117.
27. van den Oord JJ, Sarasin A, Winnepenninckx V, and Spatz A (2007). Expression profiling of melanoma cell lines: in search of a progression-related molecular signature. Future Oncol 3, 609-611.
28. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, and Weinberg RA (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563.
29. Kenny PA and Bissell MJ (2003). Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 107, 688-695.
30. Greene JF Jr, Morgan CD, Rao A, Amoss MS Jr, and Arguello F (1997). Regression by differentiation in the Sinclair swine model of cutaneous melanoma. Melanoma Res 7, 471-477.
31. Banerjee SS and Eyden B (2008). Divergent differentiation in malignant melanomas: a review. Histopathology 52, 119-129.
32. Hicks AM, Willingham MC, Du W, Pang CS, Old LJ, and Cui Z (2006). Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR mice. Cancer Immun 6, 11.
33. Jaganjac M, Poljak-Blazi M, Zarkovic K, Schaur RJ, and Zarkovic N (2008). The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma. Cancer Lett 260, 180-186.
34. Gajewski TF, Meng Y, and Harlin H (2006). Immune suppression in the tumor microenvironment. J Immunother 29, 233-240.
35. Hussein MR (2006). Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol 87, 163-176.
36. Al-Brahim N and Salama S (2005). Malignant melanoma with osteoclast-like giant cells: an unusual host response: immunohistochemical and ultrastructural study of three cases and literature review. Am J Dermatopathol 27, 126-129.
37. Handerson T, Berger A, Harigopol M, Rimm D, Nishigori C, Ueda M, Miyoshi E, Taniguchi N, and Pawelek J (2007). Melanophages reside in hypermelanotic, aberrantly glycosylated tumor areas and predict improved outcome in primary cutaneous malignant melanoma. J Cutan Pathol 34, 679-686.
38. 1,6-Branched oligosaccharides regulate melanin content and motility in macrophage-melanoma fusion hybrids. Melanoma Res 17, 9-16.
39. Yang G, Zaidi M, Zhang W, Zhu LL, Li J, Iqbal J, Varbanov A, Gross G, Phipps R, Troen BR, et al. (2008). Functional grouping of osteoclast genes revealed through microarray analysis. Biochem Biophys Res Commun 366, 352-359.
40. Raisanen SR, Alatalo SL, Ylipahkala H, Halleen JM, Cassady AI, Hume DA, and Vaananen HK (2005). Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun 331, 120-126.
41. Brown DC, Maxwell CV, Erf GF, Davis ME, Singh S, and Johnson ZB (2006). Ontogeny of T lymphocytes and intestinal morphological characteristics in neonatal pigs at different ages in the postnatal period. J Anim Sci 84, 567-578.
42. + T cells. World J Surg 19, 352-358.
43. Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, Nishimura MI, Das PK, Luiten RM, and Le Poole IC (2006). Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 5, 486-492.
44. Ruiz-Arguelles A, Brito GJ, Reyes-Izquierdo P, Perez-Romano B, and Sanchez-Sosa S (2007). Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 29, 281-286.
45. Cui J, Chen D, Misfeldt ML, Swinfard RW, and Bystryn JC (1995). Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 8, 60-63.
46. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, et al. (2001). Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 117, 326-332.
47. Herrling T, Jung K, and Fuchs J (2008). The role of melanin as protector against free radicals in skin and its role as free radical indicator in hair. Spectrochim Acta A Mol Biomol Spectrosc 69, 1429-1435.
48. Rad HH, Yamashita T, Jin HY, Hirosaki K, Wakamatsu K, Ito S, and Jimbow K (2004). Tyrosinase-related proteins suppress tyrosinase-mediated cell death of melanocytes and melanoma cells. Exp Cell Res 298, 317-328.
49. Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, and Kurnick JT (2006). Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 4, 779-792.
50. 3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res 26, 2707-2716.
51. Busam KJ, Kucukgol D, Eastlake-Wade S, Frosina D, Delgado R, and Jungbluth AA (2006). Clusterin expression in primary and metastatic melanoma. J Cutan Pathol 33, 619-623.
52. Roder JC, Lohmann-Matthes ML, Domzig W, and Wigzell H (1979). The beige mutation in the mouse: II. Selectivity of the natural killer (NK) cell defect. J Immunol 123, 2174-2181.
53. Oliver C and Essner E (1975). Formation of anomalous lysosomes in monocytes, neutrophils, and eosinophils from bone marrow of mice with Chediak-Higashi syndrome. Lab Invest 32, 17-27.